COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,823 Articles (22,968 medRxiv, 8,855 bioRxiv)

Most recent first Previous |  Page 1041: Articles 10401-10410  | Next

Molecular diagnosis of SARS-CoV-2: a validation of saliva samples
da Silva, N. V. R., Pereira, S. S. N., Kavalco, K. F., Menegidio, F. B., Medeiros-Santana, L., Visotto, L. E., Pasa, R.
10.1101/2022.01.20.22269618 — Posted: 2022-01-21
Extreme γ' fibrinogen levels in COVID-19 patients
Farrell, D. H., Hudkins, M., Hamilton, H., Underwood, S. J., Dewey, E. N., Kazmierczak, D. E., Kazmierczak, S. C., Messer, W. B., Khan, A., Schreiber, M. A.
10.1101/2022.01.20.22269321 — Posted: 2022-01-21
Aerosol measurement identifies SARS-CoV 2 PCR positive adults compared with healthy controls
Gutmann, D., Scheuch, G., Lehmkuhler, T., Herrlich, L.-S., Hutter, M., Stephan, C., Vehreschild, M., Khodamoradi, Y., Gossmann, A.-K., King, F., Weis, F., Weiss, M., Rabenau, H. F., Graf, J., Donath, H., Schubert, R., Zielen, S.
10.1101/2022.01.21.22269423 — Posted: 2022-01-21
PBPK-led guidance for the treatment of cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with the newly approved fixed dose combination nirmatrelvir-ritonavir (PAXLOVID) for the treatment of COVID-19
Hong, E., Almond, L. M., Chung, P. S., Rao, A. P., Paul, B. M.
10.1101/2022.01.20.22269253 — Posted: 2022-01-21
Elevated COVID-19 Case Rates of Government Employees, District of Columbia, 2020-22
Hua, X., Yin, J., Fung, I. C.-H.
10.1101/2022.01.18.22269410 — Posted: 2022-01-21
The impact of recurrent rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2
Menkir, T., Donnelly, C.
10.1101/2022.01.18.22269408 — Posted: 2022-01-21
The Impact of Frequent SARS-CoV-2 Testing on Weekly Case Rates Among Long-Term Care Facilities in Florida
Allan-Blitz, L., Aboabdo, B., Turner, I., Klausner, J. D.
10.1101/2022.01.18.22268929 — Posted: 2022-01-21
The Global case-fatality rate of COVID-19 has been declining disproportionately between top vaccinated countries and the rest of the world
Haider, N., Hasan, M. N., Khan, R. A., McCoy, D., Ntoumi, F., Dar, O., Ansumana, R., Uddin, M. J., Zumla, A., Kock, R. A.
10.1101/2022.01.19.22269493 — Posted: 2022-01-21 Discussion: Onsite
Effectiveness of COVID-19 Vaccines in preventing Infectiousness, Hospitalization and Mortality: A Historical Cohort Study Using Iranian Registration Data During Vaccination program
Mirahmadizadeh, A., Heiran, A., Bagheri Lankarani, K., Serati, M., Habibi, M., Eilami, O., Heiran, F., Moghadami, M.
10.1101/2022.01.18.22269330 — Posted: 2022-01-21
Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves
Lerdsamran, H., Mungaomklang, A., Iamsirithaworn, S., Prasertsopon, J., Wiriyarat, W., Saritsiri, S., Anusorntanawat, R., Siriyakorn, N., Intalapaporn, P., Sirikhetkon, S., Sangsiriwut, K., Dangsakul, W., Sawadpongpan, S., Thinpan, N., Okada, P., Techasuwanna, R., Mongkalangoon, N., Prasert, K., Puthavathana, P.
10.1101/2022.01.18.22269501 — Posted: 2022-01-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).